araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 56-year-old female with breast cancer; genetic feature: ERBB2

Clinical trial: Combined Breast Cancer Risk Study

Summary: A prospective, non-interventional study in women 18 to 84 years of age. Subjects will provide a sample for genetic testing and information about their medical and family history. The results of the genetic test will be combined with clinical data to validate a method of predicting breast cancer risk.

Detailed description: This is a prospective, non- interventional study. Women presenting at imaging centers for routine breast cancer screening or breast cancer diagnostic assessment and who provide written informed consent will undergo genetic testing. Subjects will also provide information about their personal medical and cancer history and family cancer history. The results of the genetic test will be combined with the subject's clinical information, family history, and a risk assessment model to validate a new method of predicting breast cancer.

Eligibility: Inclusion Criteria:
  Women without breast cancer:
  -  18 to 84 years of age
  -  Western/Northern European, Central/Eastern European, or Ashkenazi ancestry
  -  No history of invasive breast cancer
  Women with a history of breast cancer:
  -  18 to 84 years of age
  -  Western/Northern European, Central/Eastern European, or Ashkenazi ancestry
  -  Pathologically confirmed invasive breast cancer diagnosed within the past 12 months
  Exclusion Criteria:
  -  Unwilling to provide written informed consent.
  -  Women with history of ductal carcinoma in situ (DCIS).

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Evaluation of Factors in Human Brain Tumors

Summary: Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy). Patients that receive additional therapy can increase life expectancy to 50 weeks.
  The statistics on the life expectancy and survival have increased efforts among researchers to develop new treatments for primary malignant brain tumors.
  This research project involves the growth and study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective treatments for them.

Detailed description: This protocol involves the study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective therapeutic measures.
  Malignant primary brain tumor patients at present have a life expectancy of approximately 15 weeks following surgery unless other adjunctive measures are taken. With currently available adjunctive therapy the life expectancy reaches 50 weeks.
  These survival data have spurred extensive efforts to develop new treatment modalities. Radiation, chemotherapy and immunotherapy have been mildly helpful adjuncts but their use has been largely on empirical grounds or on the basis of experimentation on animal tumor models often quite different in nature from human brain tumors.
  Our group has sought to develop data upon which to devise new treatment strategies for patients with malignant brain tumors.
  The foundation of our approach rests upon the use of in vitro studies of the cell biology of each patient's tumor.
  It is our plan to utilize these tumors for in vitro investigation of the immunology, biology, biochemistry and molecular biology of brain tumors. Optimal conventional therapy will be given to the patients as we seek to learn more of how the scientific information obtained can be used to help them.

Eligibility: INCLUSION CRITERIA:
  Patients to be studied will have either undergone surgical confirmation of a malignant primary brain tumor or be considered likely to have that diagnosis on the basis of diagnostic studies.
  They should have survival likelihood of at least three months and be able to comprehend the nature of the proposed program.

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Familial Prostate Cancer

Summary: The purpose of this study is to identify affected individuals in families with prostate cancer and to use this information to identify genetic markers closely-linked to the disease gene.

Detailed description: The purpose of this study is to identify affected individuals in families with prostate cancer and to use this information to identify genetic markers closely-linked to the disease gene.

Eligibility: Families will be identified with two or more first degree relatives affected with prostate cancer or with one male with prostate cancer that developed before age 55.
  Must have clinical evidence of prostate cancer in the family.

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

Summary: The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.


Eligibility: Inclusion Criteria:
  -  Locally advanced or hereditary medullary thyroid cancer
  -  Signed informed consent
  -  One or more measurable lesions
  Exclusion Criteria:
  -  Brain metastases or spinal cord compression
  -  Specific laboratory ranges
  -  Specific heart problems
  -  Prior chemotherapy and/or radiation therapy
  -  Participation in other trials within 30 days

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Summary: The purpose of this study is to test the safety, tolerability and pharmacokinetic (PK) profile of AMG 386 after intravenous administration in adult subjects with advanced solid tumors.


Eligibility: Inclusion Criteria: - Have evaluable disease - Must be able to undergo MRI evaluation:
  1. Must not have cardiac pacemakers or neurostimulators not specifically approved for use in the MRI environment;
  2. Must not have metal implants, other than those approved as safe for use in MRI;
  3. Must not be claustrophobic or have physical characteristics that will preclude undergoing MRI; - Subjects enrolling to the Dose Expansion Cohort must have at least one tumor that is amenable to DCE-MRI evaluation (e.g., greater than or equal to 3 cm lesion outside the thoracic cavity) - Have Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 - Adequate hematologic, renal and hepatic function Exclusion Criteria: - Presence of untreated CNS metastasis or symptoms of brain metastases - Presence of leukemia or myelodysplastic syndrome - History of high-dose chemotherapy requiring bone marrow or peripheral stem cell support - Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure [NYHA greater than class II], uncontrolled hypertension [diastolic greater than 85 mmHg; systolic greater than 145 mmHg] or cardiac arrhythmia) - History of arterial thrombosis (i.e., stroke, transient ischemic attack or myocardial infarction) within 6 months of study day 1 - History of bleeding diathesis or hypercoagulopathy within 6 months of study day 1 - Active peptic ulcer disease or gastritis - Unresolved toxicities from prior anti-cancer therapy, excluding alopecia - Anti-tumor treatment within 3 weeks of study day 1. If anti-tumor treatment was an antibody therapy, the interval must be 6 weeks - Anticoagulation therapy, except a low dose of Coumadin™ (less than 2 mg) for prophylaxis against central catheter-related thrombosis - Major surgery within 4 weeks of study day 1 - History of allergic reaction to bacterially produced proteins - Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus or chronic hepatitis B infection - Pregnant or breastfeeding - Not using adequate contraceptive precautions, in the judgment of the investigator

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer

Summary: RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Ultrasound-guided radiofrequency ablation may be effective treatment for thyroid cancer.
  PURPOSE: This phase I trial is studying the side effects of radiofrequency ablation in treating patients who are undergoing surgery for thyroid cancer.

Detailed description: OBJECTIVES:
  -  Determine the frequency of complications associated with radiofrequency ablation (RFA) in patients with low-risk papillary thyroid cancer undergoing thyroidectomy.
  -  Determine the utility of RFA as a treatment option for these patients.
  OUTLINE: This is a pilot study.
  An electrosurgical probe is placed by ultrasound guidance into the center of the thyroid tumor. Patients undergo radiofrequency ablation directly to the tumor until the target temperature is reached* for 5 minutes. Patients then undergo standard thyroidectomy.
  NOTE: *Takes approximately 15-30 minutes to reach target temperature.
  After completion of study treatment, patients are followed at day 1, between days 14-21, and then periodically as deemed necessary.
  PROJECTED ACCRUAL: A total of 15-40 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Cytologically confirmed papillary thyroid cancer by fine needle aspiration
  -  Low-risk disease
  -  No poorly differentiated cytology
  -  Intrathyroidal tumor
  -  Located within the anterior two-thirds of the thyroid lobe
  -  Tumor not adjacent to the trachea by neck ultrasound
  -  Tumor ≤ 1.5 cm by neck ultrasound
  -  Requires thyroidectomy
  -  No cervical lymphadenopathy
  -  No multicentric tumors by neck ultrasound
  -  No evidence of lymph node metastasis
  PATIENT CHARACTERISTICS:
  Age
  -  Over 21
  Performance status
  -  Not specified
  Life expectancy
  -  Not specified
  Hematopoietic
  -  Not specified
  Hepatic
  -  Not specified
  Renal
  -  Not specified
  PRIOR CONCURRENT THERAPY:
  Biologic therapy
  -  Not specified
  Chemotherapy
  -  Not specified
  Endocrine therapy
  -  Not specified
  Radiotherapy
  -  Not specified
  Surgery
  -  Not specified

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Feasibility of Radiofrequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance.

Summary: To study the feasibility of Radiofrequency ablation (RFA) via ultrasound guidance in the treatment of papillary thyroid cancer (PTC).

Detailed description: Around 23,000 cases of thyroid cancer are discovered annually in the US, and PTC accounts for 70-75% of those cases. The conventional treatment consists mainly of surgical resection, in the form of lobectomy with/without isthmusectomy, or total thyroidectomy, making it one of the most commonly performed procedures. It has high costs, and exposes the patients to morbidity of surgery and anesthesia. PTC tends to be indolent with a 90% cure rate and controversy exists regarding extent of treatment.
  Percutaneous image-guided RFA has received increasing attention as a promising minimally invasive technique for the treatment of focal malignant disease. It permits the in situ destruction of tumors without necessitating their surgical excision.

Eligibility: Inclusion Criteria:
  -  Aged 18-90 years old
  -  Patients with low risk well-differentiated PTC, diagnosed by US guided FNA, and whose management decision is total thyroidectomy.
  -  Patients with only one dominant malignant nodule will be included in the study.
  -  Patients with size of their thyroid nodule ranging only between 1-4cm in diameter will be included in the study.
  -  Patients with nodules located only in between the mid and lower pole of the thyroid gland will be included in the study.
  Exclusion Criteria:
  -  When the patient does not meet the inclusion criteria.
  -  When the patient has a contra-indication of surgery or anesthesia.
  -  If the patient refuses involvement in the study.

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Iodine I 131 in Treating Patients With Thyroid Cancer

Summary: RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation.
  PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.

Detailed description: OBJECTIVES:
  -  Determine the relationship between estimated absorbed dose of iodine I 131 and tumor response or normal organ toxicity for different dosimetric measures, using data derived from clinical radionuclide therapy studies in patients with thyroid cancer.
  OUTLINE: Patients receive oral dosimetric iodine I 131 (^131I) on day 2 and then undergo nuclear medicine imaging at 0.5-4 hours, 24, 48, and 72 hours after dosimetric ^131I. Single-photon emission computed tomography (SPECT)/CT scans are performed at 0.5-4 hours and 24 or 48 hours over the head and neck region, including the salivary glands. Subsequent SPECT/CT scans are performed over the candidate tumor sites. Patients undergo ^131I therapy on day 11.
  Saliva is collected on days 1 and 2, weeks 2 and 4, and months 3 and 6 to measure saliva flow rate. Blood is collected at baseline and periodically during study to measure FLT3 ligand levels.
  PROJECTED ACCRUAL: A total of 96 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Diagnosis of thyroid cancer
  -  Measurable disease by CT scan or nuclear medicine imaging
  -  Eligible, by standard of care criteria, for iodine I 131 therapy
  PATIENT CHARACTERISTICS:
  -  Not pregnant or nursing
  -  Negative pregnancy test
  -  Fertile patients must use effective non-barrier method contraception (e.g., combined or progesterone-only oral contraceptive pill, intrauterine device, depot progesterone, or stable relationship with a partner who has had a vasectomy)
  -  No other malignancy within the past 5 years except squamous cell or basal cell carcinoma of the skin
  -  No nonthyroidal conditions known to affect iodine I 131 uptake (e.g., New York Heart Association class III or IV congestive heart failure or renal failure)
  -  No alcoholism or drug abuse within the past 2 years
  -  No severe emotional, behavioral, or psychiatric problems that would preclude study compliance (e.g., severe claustrophobia)
  PRIOR CONCURRENT THERAPY:
  -  No intravenous water-soluble radiographic contrast within the past 4 weeks
  -  No iodinated contrast agent within the past 3 months
  -  No concurrent drugs that may affect thyroid or renal function (e.g., renal drugs, lithium, amiodarone, other iodine-containing medication, or corticosteroids)
  -  No other concurrent investigational drugs

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma

Summary: The purpose of this study is to investigate the relationship between prognosis and fine needle aspiration cytology character of papillary thyroid cancer.

Detailed description: Papillary thyroid carcinoma is the most common thyroid malignancy worldwide. The influence of clinicopathologic features on prognosis has been examined, but the relationship between cytologic features obtained by fine-needle aspiration (FNA) and prognosis has been minimally studied. We retrospectively studied the cytologic features with computerized morphometry in 83 patients with usual-type papillary thyroid cancer and followed them for more than 10 years except for one with metastasis at diagnosis. The cytologic features of FNA and recurrence of cancer were examined statistically.

Eligibility: Inclusion Criteria:
  -  Papillary thyroid cancer diagnosed in NTUH from 1977 to 2000
  Exclusion Criteria:
  -  Patient without complete medical record

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma

Summary: Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)


Eligibility: Inclusion Criteria:
  -  18 -75 years
  -  Karnofsky ≥ 70%
  -  Histological diagnosis of medullary thyroid carcinoma
  -  Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years
  -  Normal liver and renal functions
  -  Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3
  -  No immunization
  -  Consent form signed

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Postpartum Thyroid Measures and Mood

Summary: Women with abnormal serum thyroid antibody levels or abnormal TSH and/or T4 values are more likely than their normal counterparts to have higher scores on a common postpartum depression screening test.

Detailed description: This small pilot study was an attempt to corroborate a relationship between quantified mood and thyroid measures, using the numerical scores obtained from a common depression screen, the Edinburgh Postnatal Depression Scale (EPDS), as a continuum. Mood scores were compared with presence of thyroid autoantibodies and plasma concentrations of free T4 and TSH.

Eligibility: Inclusion Criteria:
  -  Over 18 years of age
  -  In third trimester of pregnancy when recruited
  -  Negative for the following drugs detected by a urine drug screen:
  -  Amphetamines
  -  Barbiturates
  -  Benzodiazepines
  -  Cocaine
  -  Opiates
  -  Phencyclidine metabolites (PCP), and tricyclic antidepressants
  -  Vaginal delivery
  -  Screened negative for major depressive disorder on the Edinburgh Postnatal Depression Scale (EPDS) at her prenatal enrollment in the study
  -  Receiving a score of 12 or lower out of a possible 30
  Exclusion Criteria:
  -  Under age 18
  -  Positive for any of the following drugs:
  -  Amphetamines
  -  Barbiturates
  -  Benzodiazepines
  -  Cocaine
  -  Opiates
  -  Phencyclidine metabolites (PCP), and tricyclic antidepressants
  -  Cesarean delivery
  -  EPDS score over 12 at prenatal screening test

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer

Summary: To evaluate quality of life in patients after 10 days pause of thyroid medication (Liothyronine) compared to treatment with recombinant TSH (Thyrogen) before radioiodine uptake and treatment in a double-blinded, randomised cross-over design.

Detailed description: Patients with a thyroid follicular or papillary cancer referred to radioiodine treatment in oncological department . The patients after thyroidectomy will be treated with Liothyronine and this treatment will be paused 10 days before radioiodine. As a routine these patients will be re-evaluated with iodine uptake 4 months later.
  The patients will be randomised to either T3 pause related to the first radioiodine treatment and Thyrogen injection (recombinant TSH) related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
  All medication given in the 10 days period right before radioiodine treatment/uptake will be delivered to the patients and marked with a protocol number. In the period with T3 pause the patients will be given placebo tablets and an injection of saline (instead of Thyrogen) before treatment/uptake at the similar time as given the Thyrogen injection. A nurse otherwise not involved in the study will give the injection.
  Patients will be evaluated by VAS, SF-36, and Eortc QLC30 (version 2.0) before radioiodine treatment and 3 weeks after treatment.

Eligibility: Inclusion Criteria:
  -  Follicular or papillary thyroid cancer
  Exclusion Criteria:
  -  < 18 or > 75 years old
  -  Pregnant or lactating women

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection

Summary: the increased risk of hypocalcemia following total thyroidectomy plus central neck dissection can be minimized by routine administration of oral calcium and vitamin D supplements during the early postoperative period.

Detailed description: Of patients with differentiated papillary thyroid carcinoma, group D underwent total thyroidectomy alone and groups A-C underwent total thyroidectomy plus CND. The latter were randomized to oral calcium (3 g/day) plus vitamin D (1 mcg/day) (group A, n = 49), calcium alone (group B, n = 49), or no supplements (group C, n = 50). Hypocalcemic symptoms, serum calcium, and parathyroid hormone (PTH) levels were compared among the groups.

Eligibility: Inclusion Criteria:
  -  Differentiated papillary thyroid carcinoma
  -  Undergoing total thyroidectomy plus central neck dissection
  Exclusion Criteria:
  -  Previous thyroid or neck surgery
  -  Patients with parathyroid diseases
  -  Other thyroid malignancies
  -  Early loss of follow-up without proper evaluation of postoperative serum calcium levels and symptoms

Relevance to patient case: not relevant